Literature DB >> 9437229

The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations.

E Arvat1, J Ramunni, J Bellone, L Di Vito, C Baffoni, F Broglio, R Deghenghi, E Bartolotta, E Ghigo.   

Abstract

Hexarelin (HEX) is a synthetic growth hormone-releasing peptide (GHRP) which acts on specific receptors at both the pituitary and the hypothalamic level to stimulate GH release in an age-dependent manner. Like other GHRPs, HEX possesses also prolactin (PRL) and ACTH/cortisol-releasing activity. similar to that of human corticotropin-releasing hormone (hCRH). The mechanisms underlying the stimulatory effect of GHRPs on lactotrope and corticotrope secretion are even less clear and the influence of age on these endocrine activities of GHRPs is unknown. To clarify this point we studied the GH, PRL, ACTH and cortisol responses to the maximal effective dose of HEX (2.0 micrograms/kg i.v.) in: 12 prepubertal children (Pre-C, 8 male, 4 female, age 5.8-12.1 years); 12 pubertal normal short children (Pub-C, 5 male, 7 female, age 9.7-15.5 years, pubertal stage II-IV); 20 normal young adults (Young, 6 males, 14 females, age 23-32 years); and in 16 normal elderly people (Elderly, 5 male, 11 female, age 66-81 years). The GH response to HEX was clear in Pre-C (0-120 min area under curve, mean +/- S.E.M. 769.5 +/- 122.2 micrograms*min/l) but strikingly increased (P < 0.001) in Pub-C (1960.2 +/- 283.5 micrograms*min/l). The HEX-induced GH rise in Young (1829.7 +/- 243.1 micrograms*min/l) persisted similar to that in Pub-C, but decreased in Elderly (951.1 +/- 232.9 micrograms*min/I, P < 0.005); the latter was, in turn, similar to that in Pre-C. HEX induced a significant PRL increase which, however, showed no age-related variations, being similar in Pre-C (512.1 +/- 88.0 micrograms*min/l), Pub-C (584.0 +/- 106.0 micrograms*min/l), Young (554.9 +/- 56.0 micrograms*min/l) and Elderly (523.9 +/- 59.6 micrograms*min/l). The ACTH-releasing activity of HEX was present in Pre-C (1356.6 +/- 204.9 pg*min/ml) and was clearly enhanced (P < 0.02) in Pub-C (2253.5 +/- 242.8 pg*min/ml). The ACTH rise after HEX in Young (1258.1 +/- 141.2pg*min/ml) was lower (P < 0.02) than that in Pub-C and similar to that in Pre-C, while the ACTH response to HEX in Elderly (1786.5 +/- 340.1 pg*min/ml) showed a further trend toward increase, being similar to that in Pub-C. On the other hand, the cortisol response to HEX showed no significant age-related variations, being not different in Pre-C (7747.2 +/- 1031.6 micrograms*min/l), Pub-C (6106.0 +/- 862.9 micrograms*min/l), Young (6827.5 +/- 509.6 micrograms*min/I) and Elderly (7950.6 +/- 658.3 micrograms*min/l). In conclusion, our present data demonstrate that in humans the GH- and ACTH-releasing activities of HEX undergo different age-related variations, while its PRL-releasing activity is not dependent on age. These finding suggest that actions at different levels and/or on different receptor subtypes mediate the different age-related hormonal effects of GHRPs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9437229     DOI: 10.1530/eje.0.1370635

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  8 in total

Review 1.  Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system.

Authors:  E Arvat; L Gianotti; R Giordano; F Broglio; M Maccario; F Lanfranco; G Muccioli; M Papotti; A Graziani; E Ghigo; R Deghenghi
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 2.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.

Authors:  E Arvat; L Di Vito; F Lanfranco; F Broglio; R Giordano; A Benso; G P Muccioli; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

4.  Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.

Authors:  L Gianotti; J Ramunni; F Lanfranco; B Maccagno; R Giordano; F Broglio; M Maccario; E E Muller; E Ghigo; E Arvat
Journal:  J Endocrinol Invest       Date:  2001-02       Impact factor: 4.256

5.  Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.

Authors:  S Grottoli; E Arvat; C Gauna; B Maccagno; J Ramunni; R Giordano; M Maccario; R Deghenghi; E Ghigo
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

6.  GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal.

Authors:  M R A Martins; A C A R Pinto; E Brunner; M R D Silva; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

Review 7.  Biologic activities of growth hormone secretagogues in humans.

Authors:  E Ghigo; E Arvat; R Giordano; F Broglio; L Gianotti; M Maccario; G Bisi; A Graziani; M Papotti; G Muccioli; R Deghenghi; F Camanni
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.925

Review 8.  Sex-steroid modulation of growth hormone (GH) secretory control: three-peptide ensemble regulation under dual feedback restraint by GH and IGF-I.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.925

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.